UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Metabolic reprogramming in clear cell renal cell carcinoma

Nature reviews. Nephrology, 2017-07, Vol.13 (7), p.410

2017

Link zum Volltext

Verfügbarkeit prüfen

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Cell, 2018-07, Vol.174 (3), p.758-769.e9

2018

Link zum Volltext

Verfügbarkeit prüfen

Aurora Kinases as Anticancer Drug Targets

Clinical cancer research, 2008-03, Vol.14 (6), p.1639-1648

2008

Link zum Volltext

Verfügbarkeit prüfen

Squamous cell lung cancer: from tumor genomics to cancer therapeutics

Clinical cancer research, 2015-05, Vol.21 (10), p.2236-2243

2015

Link zum Volltext

Verfügbarkeit prüfen

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1560-1568

2018

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Journal of clinical oncology, 2013-02, Vol.31 (4), p.412-419

2013

Link zum Volltext

Verfügbarkeit prüfen

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

Oncogene, 2023-02, Vol.42 (9), p.693-707

2023

Link zum Volltext

Verfügbarkeit prüfen

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2022-01, Vol.20 (1), p.71

2022

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

The New England journal of medicine, 2004-10, Vol.351 (15), p.1513-1520

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-08, Vol.29 (22), p.2965-2971

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational new drugs, 2014-02, Vol.32 (1), p.178-187

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2530-2535

2009

Link zum Volltext

Verfügbarkeit prüfen

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet (British edition), 2021-02, Vol.397 (10275), p.695-703

2021

Link zum Volltext

Verfügbarkeit prüfen

Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases

The New England journal of medicine, 2015-11, Vol.373 (19), p.1872-1874

2015

Link zum Volltext

Verfügbarkeit prüfen

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European urology, 2024-02, Vol.85 (2), p.171-176

2024

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2218-2224

2007

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6309-6319

2019

Link zum Volltext

Verfügbarkeit prüfen

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Journal of clinical oncology, 2008-01, Vol.26 (3), p.463-467

2008

Link zum Volltext

Verfügbarkeit prüfen

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3540-3546

2009

Link zum Volltext

Verfügbarkeit prüfen

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

Nature communications, 2019-10, Vol.10 (1), p.4621-17, Article 4621

2019

Link zum Volltext

Verfügbarkeit prüfen

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Cell, 2018-10, Vol.175 (3), p.889-889

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet (British edition), 2023-09, Vol.402 (10407), p.1043-1051

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Scientific reports, 2021-03, Vol.11 (1), p.6377-6377, Article 6377

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 412

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(400)
Mit Volltextzugriff
(387)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(243)
Life Sciences & Biomedicine
(241)
Humans
(232)
Oncology
(205)
Male
(147)
Middle Aged
(115)
Aged
(113)
Female
(95)
Adult
(78)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(77)
Lung Neoplasms - Drug Therapy
(75)
Aged, 80 And Over
(74)
Biological And Medical Sciences
(73)
Medical Sciences
(73)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(58)
Treatment Outcome
(55)
Tumors
(47)
Urology & Nephrology
(46)
Antineoplastic Agents - Therapeutic Use
(41)
Lung Neoplasms - Pathology
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Metabolic reprogramming in clear cell renal cell carcinoma

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Aurora Kinases as Anticancer Drug Targets

Squamous cell lung cancer: from tumor genomics to cancer therapeutics

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Suchergebnisse filtern